OT-58 for Homocystinuria
Contact
Description
Eligibility and criteria
IRB Number:
18-015157
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:
What to expect
- Part A involves 6 weeks of study drug doses. The first and last day of study drug dosing require you to stay overnight at CHOP. You will be admitted on the day of dosing, and you will stay for approximately 24 hours (overnight stay).
- Part B: If your homocystinuria does not get worse and you do not have any bad side effects, you will be able to begin Part B. In Part B you will continue to receive the treatment and dose you received in Part A. If you are in one of the early dose groups and the dose of study drug does not give a strong enough response, your dose and dose frequency may be increased.
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.